Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

21 Aug 2018

Abstract excerpt

Abstract Purpose: Ewing sarcoma (ES) is a rare and highly malignant cancer that occurs in the bone and surrounding tissue of children and adolescents. The EWS/ETS fusion transcription factor that drives ES pathobiology was previously demonstrated to modulate cyclin D1 expression. In this study, we evaluated abemaciclib, a small-molecule CDK4 and CDK6 (CDK4 and 6) inhibitor currently under clinical investigation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to FOXO transcription factor regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30131386
DOI: 10.1158/1078-0432.ccr-18-1256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingPMID 30131386Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma CellsSemantic proximity Read ↗

A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcomaSemantic proximity Read ↗

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcomaSemantic proximity Read ↗

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity Read ↗

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor GrowthSemantic proximity Read ↗

Non-Genetic Mechanisms of Fractional Resistance to Abemaciclib in Dedifferentiated LiposarcomaSemantic proximity Read ↗

An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing SarcomaSemantic proximity Read ↗

Ewing Sarcoma: Biology-Based Therapeutic PerspectivesSemantic proximity Read ↗

CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic TargetsSemantic proximity Read ↗

CK2 inhibitor CX-4945 targets EWS-FLI1 signaling network and shows therapeutic efficacy in metastatic mouse models of Ewing SarcomaSemantic proximity Read ↗

Ewing and Ewing-like-sarcoma tumoroid biobank reveals distinct drug sensitivities: translocation makes the differenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.